3.13
-0.08 (-2.49%)
| Penutupan Terdahulu | 3.21 |
| Buka | 3.17 |
| Jumlah Dagangan | 2,417,696 |
| Purata Dagangan (3B) | 2,750,048 |
| Modal Pasaran | 627,154,944 |
| Harga / Jualan (P/S) | 2.55 |
| Harga / Buku (P/B) | 8.51 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Jul 2026 |
| Margin Keuntungan | -10.23% |
| Margin Operasi (TTM) | -13.54% |
| EPS Cair (TTM) | -0.100 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 12.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 176.82% |
| Nisbah Semasa (MRQ) | 2.32 |
| Aliran Tunai Operasi (OCF TTM) | 8.56 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 7.81 M |
| Pulangan Atas Aset (ROA TTM) | -3.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -35.69% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Cerus Corporation | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.5 |
| Purata | -0.67 |
|
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.35% |
| % Dimiliki oleh Institusi | 76.13% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |